Taiho Oncology, Inc.

Taiho Oncology, Inc. logo
🇺🇸United States
Ownership
Subsidiary
Established
2002-01-01
Employees
251
Market Cap
-
Website
http://www.taihooncology.com

Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.

First Posted Date
2024-07-18
Last Posted Date
2024-10-31
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
15
Registration Number
NCT06506955
Locations
🇺🇸

University of California, San Francisco (UCSF), San Francisco, California, United States

REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)

First Posted Date
2023-08-03
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
272
Registration Number
NCT05973773
Locations
🇧🇪

Algemeen Ziekenhuis Delta - Campus Menen, Menen, West Flanders, Belgium

🇹🇭

Faculty of Medicine Siriraj Hospital, Bang Phlat, Bangkok, Thailand

🇹🇭

King Chulalongkorn Memorial Hospital, Pathum Wan, Bangkok, Thailand

and more 89 locations

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

First Posted Date
2023-08-01
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
160
Registration Number
NCT05967689
Locations
🇺🇸

O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

City of Hope - Duarte (Main Campus), Duarte, California, United States

🇺🇸

City of Hope - Huntington Beach, Huntington Beach, California, United States

and more 86 locations

Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors

First Posted Date
2023-07-14
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
66
Registration Number
NCT05945823
Locations
🇺🇸

University of California Los Angeles UCLA - Cancer Care - Santa Monica, Santa Monica, California, United States

🇺🇸

Rocky Mountain Cancer Centers Midtown, Denver, Colorado, United States

🇺🇸

Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida, United States

and more 19 locations

A Study of TAS3351 in NSCLC Patients With EGFRmt

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2023-03-13
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
200
Registration Number
NCT05765734
Locations
🇺🇸

Georgetown University - Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States

🇺🇸

Tennessee Oncology, Nashville, Tennessee, United States

🇺🇸

University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

and more 14 locations

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

First Posted Date
2023-02-14
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
120
Registration Number
NCT05727176
Locations
🇺🇸

University of California San Diego UCSD - Moores Cancer Center, La Jolla, California, United States

🇺🇸

Tampa General Hospital Cancer Institute, Tampa, Florida, United States

🇺🇸

Henry Ford Health System, Detroit, Michigan, United States

and more 53 locations

A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)

First Posted Date
2022-06-03
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
132
Registration Number
NCT05403450
Locations
🇺🇸

Rochester Skin Lymphoma Medical Group, PLLC Site #147, Fairport, New York, United States

🇺🇸

University of Pennsylvania Site# 160, Philadelphia, Pennsylvania, United States

🇦🇺

Monash Medical Center, Melbourne, Victoria, Australia

and more 43 locations

A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer

Phase 1
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-07-29
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
42
Registration Number
NCT04982926
Locations
🇺🇸

Tennessee Oncology, Nashville, Tennessee, United States

🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

🇫🇷

CLCC Gustave Roussy, Villejuif, Cedex, France

Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer

First Posted Date
2021-07-16
Last Posted Date
2024-06-27
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
38
Registration Number
NCT04965818
Locations
🇺🇸

Community Cancer Center North, Indianapolis, Indiana, United States

🇺🇸

University of California Los Angeles UCLA Cancer, Santa Monica, California, United States

🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2021-07-08
Last Posted Date
2024-12-02
Lead Sponsor
Taiho Oncology, Inc.
Target Recruit Count
27
Registration Number
NCT04953910
Locations
🇧🇬

Complex Oncology Center - Plovdiv - Base II, Plovdiv, Bulgaria

🇱🇹

BIO1, Vilnius, Lithuania

🇵🇱

Centrum Badań Klinicznych Piotr Napora Lekarze Sp. p., Wrocław, Poland

and more 8 locations
© Copyright 2024. All Rights Reserved by MedPath